Cargando...
GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...
Gardado en:
| Publicado en: | BMC Med Inform Decis Mak |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7469913/ https://ncbi.nlm.nih.gov/pubmed/32580715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12911-020-01149-3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|